Switch to:
Also traded in: Australia

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt N/A
GENE's Cash-to-Debt is ranked higher than
99% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. GENE: N/A )
Ranked among companies with meaningful Cash-to-Debt only.
GENE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.85  Med: 38.8 Max: No Debt
Current: N/A
Equity-to-Asset 0.89
GENE's Equity-to-Asset is ranked higher than
92% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. GENE: 0.89 )
Ranked among companies with meaningful Equity-to-Asset only.
GENE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.83 Max: 0.93
Current: 0.89
0.09
0.93
Debt-to-Equity N/A
GENE's Debt-to-Equity is ranked lower than
99.99% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. GENE: N/A )
Ranked among companies with meaningful Debt-to-Equity only.
GENE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.03 Max: 4.95
Current: N/A
0
4.95
Piotroski F-Score: 3
Altman Z-Score: -5.29
Beneish M-Score: -2.09
WACC vs ROIC
24.13%
-1440.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1068.26
GENE's Operating Margin % is ranked lower than
93% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. GENE: -1068.26 )
Ranked among companies with meaningful Operating Margin % only.
GENE' s Operating Margin % Range Over the Past 10 Years
Min: -793.07  Med: -94.68 Max: 6.75
Current: -1068.26
-793.07
6.75
Net Margin % -976.61
GENE's Net Margin % is ranked lower than
92% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. GENE: -976.61 )
Ranked among companies with meaningful Net Margin % only.
GENE' s Net Margin % Range Over the Past 10 Years
Min: -751.91  Med: -92.71 Max: 4.93
Current: -976.61
-751.91
4.93
ROE % -57.68
GENE's ROE % is ranked lower than
75% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. GENE: -57.68 )
Ranked among companies with meaningful ROE % only.
GENE' s ROE % Range Over the Past 10 Years
Min: -271.23  Med: -52.78 Max: 14.99
Current: -57.68
-271.23
14.99
ROA % -52.26
GENE's ROA % is ranked lower than
75% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. GENE: -52.26 )
Ranked among companies with meaningful ROA % only.
GENE' s ROA % Range Over the Past 10 Years
Min: -134.56  Med: -45.72 Max: 10.58
Current: -52.26
-134.56
10.58
ROC (Joel Greenblatt) % -1384.62
GENE's ROC (Joel Greenblatt) % is ranked lower than
89% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. GENE: -1384.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GENE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2298.65  Med: -535.14 Max: 65.76
Current: -1384.62
-2298.65
65.76
3-Year Revenue Growth Rate -61.10
GENE's 3-Year Revenue Growth Rate is ranked lower than
95% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. GENE: -61.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GENE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.65 Max: 39.5
Current: -61.1
0
39.5
3-Year EBITDA Growth Rate -37.00
GENE's 3-Year EBITDA Growth Rate is ranked lower than
94% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. GENE: -37.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GENE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -6.55 Max: 31
Current: -37
0
31
3-Year EPS without NRI Growth Rate -37.00
GENE's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. GENE: -37.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GENE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.7 Max: 27.7
Current: -37
0
27.7
GuruFocus has detected 7 Warning Signs with Genetic Technologies Ltd $GENE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GENE's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GENE Guru Trades in Q3 2016

Jim Simons 486,680 sh (+20.62%)
» More
Q4 2016

GENE Guru Trades in Q4 2016

Jim Simons 679,080 sh (+39.53%)
» More
Q1 2017

GENE Guru Trades in Q1 2017

Jim Simons 837,380 sh (+23.31%)
» More
Q2 2017

GENE Guru Trades in Q2 2017

Jim Simons 942,180 sh (+12.52%)
» More
» Details

Insider Trades

Latest Guru Trades with GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414    SIC: 2836
Compare:ASX:LSH, ASX:PAA, ASX:BD1, ASX:CTE, ASX:IBX, ASX:GSS, ASX:OSL, ASX:DVL, ASX:CMP, ASX:OBJ, ASX:IDX » details
Traded in other countries:GTG.Australia,
Headquarter Location:Australia
Genetic Technologies Ltd is a molecular diagnostics company. It offers predictive testing and assessment tools to help physicians manage women's health.

Genetic Technologies Ltd is incorporated in Australia on January 05, 1987. The Company is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.

Top Ranked Articles about Genetic Technologies Ltd

Genetic Technologies Transitions to Online Commercial Platform for BREVAGenplus®
Genetic Technologies Launches BREVAGenplus(R) Marketing Program Around Susan G. Komen(R)'s Race for the Cure(R) Events

MELBOURNE, AUSTRALIA--(Marketwired - Oct 3, 2016) - Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") announced today that it will be conducting a promotional campaign around the Susan G. Komen Race for the Cure events. This program will commence at the Susan G. Komen Dallas Race for the Cure in Dallas, on October 15 2016, which coincides with National Breast Cancer Awareness Month. Two contests will anchor the initiative and will feature, in person, BREVAGenplus spokesperson and Susan G. Komen advocate, Verizon IndyCar series driver, Pippa Mann. "We are pleased to join Susan G. Komen in the world's largest fundraising initiative to fight breast cancer," commented Mr. Eutillio Buccilli, Chief Executive Officer of Genetic Technologies Limited. "By participating at these Race for the Cure events we reaffirm our commitment to supporting the important work Komen does on behalf of the breast cancer community. We are pleased to have Pippa on site in Dallas for this Race to help us raise awareness of the importance risk assessment plays in the prevention and early detection of the disease." Participants who visit the BREVAGenplus booth, which will be located in the Sponsor Expo Area, south of the Main Stage, will be encouraged to fill out the BREVAGenplus Quiz at that time, and will be entered to win an iPad mini. Pippa will be present at the booth to greet participants and to discuss the threat represented by breast cancer and the importance of risk assessment, especially for women with little to no family history. Breast cancer will affect 1 in 8 women during their lifetime. In parallel, the Company will be conducting a social media contest whereby the first 100 participants will receive a signed Pippa Mann poster. In order to enter the contest, participants need to re-tweet or share one of BREVAGenplus' social media posts or use the hashtag #KnowYourRisk. About Genetic Technologies Limited

Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus® improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus® expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer. The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus®, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com. About Susan G. Komen® and Susan G. Komen® Dallas County

Susan G. Komen is the world's largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. Komen was founded in 1982 by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life. Komen Dallas County is working to better the lives of those facing breast cancer in the local community. Through events like the Komen Dallas Race for the Cure, Komen Dallas County has invested over $24 million in community breast health programs in Dallas County and has contributed to the more than $920 million invested globally in research. For more information about Komen Dallas County, call 214-750-7223 or visit www.komen-dallas.org. Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.


FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Eutillio Buccilli

Executive Director & Chief Executive Officer

Genetic Technologies Limited

61 3 8412 7050


Candice Knoll (USA)

Blueprint Life Science Group

1 (415) 375 3340, Ext. 4





Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.11
GENE's PB Ratio is ranked higher than
94% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. GENE: 1.11 )
Ranked among companies with meaningful PB Ratio only.
GENE' s PB Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.58 Max: 23.33
Current: 1.11
0.7
23.33
EV-to-EBIT -2.02
GENE's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. GENE: -2.02 )
Ranked among companies with meaningful EV-to-EBIT only.
GENE' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.9  Med: -1.6 Max: 133.8
Current: -2.02
-40.9
133.8
EV-to-EBITDA -2.11
GENE's EV-to-EBITDA is ranked lower than
99.99% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. GENE: -2.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
GENE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.6  Med: -1.7 Max: 164.8
Current: -2.11
-27.6
164.8
EV-to-Revenue 20.34
GENE's EV-to-Revenue is ranked higher than
72% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. GENE: 20.34 )
Ranked among companies with meaningful EV-to-Revenue only.
GENE' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 3 Max: 20.6
Current: 20.34
0.1
20.6
Days Sales Outstanding 319.70
GENE's Days Sales Outstanding is ranked lower than
97% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. GENE: 319.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
GENE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.06  Med: 34.6 Max: 127.51
Current: 319.7
13.06
127.51
Days Payable 192.57
GENE's Days Payable is ranked higher than
87% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. GENE: 192.57 )
Ranked among companies with meaningful Days Payable only.
GENE' s Days Payable Range Over the Past 10 Years
Min: 62.36  Med: 178.73 Max: 357.55
Current: 192.57
62.36
357.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.40
GENE's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. GENE: -53.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GENE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -54.5  Med: -7.2 Max: 0
Current: -53.4
-54.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.11
GENE's Price-to-Tangible-Book is ranked higher than
95% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. GENE: 1.11 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GENE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.11  Med: 4.43 Max: 40
Current: 1.11
1.11
40
Earnings Yield (Greenblatt) % -49.50
GENE's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. GENE: -49.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GENE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -383.2  Med: -42.7 Max: 3.5
Current: -49.5
-383.2
3.5

More Statistics

Revenue (TTM) (Mil) $0.62
EPS (TTM) $ -0.51
Beta3.78
Short Percentage of Float0.00%
52-Week Range $0.70 - 2.89
Shares Outstanding (Mil)16.24 (ADR)
» More Articles for GENE

Headlines

Articles On GuruFocus.com
Genetic Technologies Transitions to Online Commercial Platform for BREVAGenplus® Sep 21 2017 
Genetic Technologies Launches BREVAGenplus(R) Marketing Program Around Susan G. Komen(R)'s Race for Oct 03 2016 
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing P Jun 22 2016 
Genetic Technologies Announces Appointment of Senior Medical Director Jun 21 2016 
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market Closin May 04 2016 
Genetic Technologies and IndyCar's Pippa Mann Announce Partnership to Promote BREVAGenplus(R) Feb 22 2016 
Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of BREVAG Dec 21 2015 
Genetic Technologies Granted Key Patents by US Patent Office for BREVAGenplus(R) Aug 06 2015 
Genetic Technologies Announces Scientific Validation, Clinical Trial and Peer Review Publication Ini Jul 14 2015 
Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer Feb 26 2015 

More From Other Websites
Genetic Technologies Transitions to Online Commercial Platform for BREVAGenplus® Sep 21 2017
Genetic Technologies Ltd. :GENE-US: Earnings Analysis: For the six months ended June 30, 2017 :... Sep 01 2017
Corporate News Blog - Genetic Technologies Announces Comprehensive Review of Strategic Alternatives Aug 28 2017
Genetic Technologies Announces Comprehensive Review of Strategic Alternatives Aug 25 2017
Genetic Technologies Launches Breast Cancer Awareness Month Promotion for BREVAGenplus(R) Aug 01 2017
Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules... Jul 27 2017
Genetic Technologies Receives Nasdaq Deficiency Notice Jul 21 2017
Genetic Technologies Revamps Patient Pricing and Billing Program for BREVAGenplus(R) Mar 31 2017
Genetic Technologies and IndyCar's Pippa Mann Partner for Second Consecutive Year to Promote... Mar 29 2017
Genetic Technologies Ltd. :GENE-US: Earnings Analysis: For the six months ended December 31, 2016 :... Feb 24 2017
Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares Dec 01 2016
Genetic Technologies Limited and The University of Melbourne Enter into Exclusive Worldwide License... Nov 29 2016
Genetic Technologies Launches BREVAGenplus(R) Marketing Program Around Susan G. Komen(R)'s Race for... Oct 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}